Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer
Lujie Yang, Jinli Cheng, Xin Guo, He Xiao, Xunjie Kuang, Yuxin Yang, Lei Zhang, Qin Zhang, Dong Wang, Yu Xu, Mengxia Li · 2026
Read Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer by Lujie Yang, Jinli Cheng, Xin Guo, He Xiao, Xunjie Kuang, Yuxin Yang, Lei Zhang, Qin Zhang, Dong Wang, Yu Xu, Mengxia Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13317226.txt.
Description
Lujie Yang and co-authors study DNA repair gene flaws in lung cancer treated with targeted drugs in a 2026 paper. Such drugs help many patients whose tumors carry a growth gene change, yet tumors adapt and resist in time. Faulty repair genes make genomes shaky, which may hasten that escape.
Repair flaws were common in the large group scanned. Patients with such flaws saw their disease return sooner on the drugs and carried more gene changes overall. Two repair paths stood out as strong risk marks. Those with both repair flaws and a second gene flaw fared worst. Gene scans could flag this high-risk group early.
Catalog record
| CREATOR | Lujie Yang, Jinli Cheng, Xin Guo, He Xiao, Xunjie Kuang, Yuxin Yang, Lei Zhang, Qin Zhang, Dong Wang, Yu Xu, Mengxia Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |